GW873140 In Combination With Combivir In HIV Infected Subjects

• HIV infected subjects.
• Females must be of either non-childbearing age, or have a negative pregnancy test.
• All subjects participating in this study should be counseled on the practice of safe sex using a proven double barrier method of contraception throughout the study.
• Screening lab result of plasma HIV-1 RNA greater than or equal to 10,000 copies/mL and CD4 cell count greater than or equal to 100 cells/mm3.
• Have CC Chemokine Receptor5-tropic (R5-tropic) virus based on viral tropism test at screening visit.
• Have no drug resistance mutations in HIV-1 Reverse Transcriptase based on resistance test at screening visit.
• Be treatment-naive, defined as less than or equal to 2 weeks of treatment with a protease inhibitor (PI) or a nucleoside reverse transcriptase inhibitor/nucleotide reverse transcriptase inhibitor (NRTI/ NtRTI), or less than or equal to 7 days of therapy with a non-nucleoside reverse transcriptase inhibitor (NNRTI).
• Prior treatment with any entry inhibitor, attachment inhibitor, or fusion inhibitor (experimental or approved) is not allowed.
• Be able to understand and follow with protocol requirements, instructions and protocol-stated restrictions.
• Signed and dated written informed consent prior to study entry.

Exclusion criteria:

• Detection of any CXC Receptor4-tropic (X4-tropic) virus, based on viral tropism test at screening.
• Any drug resistance mutations in HIV-1 Reverse Transcriptase based on resistance test at screening visit.
• Active Class C AIDS-defining illness.
• Laboratory abnormalities at screen.
• Significant blood loss prior to study start.
• Pregnant or breastfeeding women.
• Additional qualifying criteria to be determined by the physician.